Mustafa Khasraw

As TIL therapies move beyond melanoma into more complex tumor types, new biological and manufacturing challenges emerge. This session explores the interplay between tumor biology, starting material quality, and therapeutic end-points, highlighting strategies to enhance efficacy across diverse indications.